<DOC>
	<DOCNO>NCT01735422</DOCNO>
	<brief_summary>This single center , open-label , randomize , parallel group , dose find study evaluate safety efficacy recombinant human luteinizing hormone ( r-hLH , LHadi速 ) , compare urinary human chorionic gonadotrophin ( u-hCG , Profasi速 ) , give subcutaneously , induce ovulation infertile woman undergo stimulation follicular growth recombinant human follicle stimulate hormone ( r-hFSH , Gonal-F速 ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Recombinant Human Luteinizing Hormone ( r-hLH ) Compared With Urinary Human Chorionic Gonadotrophin ( u-hCG ) Trigger Ovulation Infertile Women</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Infertile woman wish conceive justifying ovarian stimulation treatment gonadotrophin vivo conception Aged 2040 year ( inclusive ) Male partner acceptable semen analysis intrauterine insemination , accord center 's standard practice Have follow hormone serum level measure locally early ( Day 24 ) follicular phase ( menstruate ) anytime ( menstruate ) : Follicle stimulate hormone ( FSH ) less 12 international unit per liter ( IU/L ) Prolactin ( PRL ) less 800 milli international unit per liter ( mIU/l ) Lutenizing hormone ( LH ) , P4 , Testosterone ( T ) Dehydroepiandrosterone sulphate ( DHEAS ) documentation purpose At least one patent tube , assess hysterosalpingography ( HSG ) , ultrasound ( U/S ) laparoscopy perform within 3 year prior begin rhFSH treatment Uterine cavity without abnormality , Investigator 's opinion , could impair embryo implantation pregnancy evolution assess HSG , hysteroscopy ( HSC ) U/S perform within 3 year prior begin rhFSH treatment Body mass index ( BMI ) great equal 18 less equal 35 kilogram per square meter ( kg/m^2 ) Negative serum urinary pregnancy test prior begin rhFSH treatment Be willing able comply protocol duration study Have give write informed consent , prior studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care Any contraindication pregnant and/or carry pregnancy term Clinically significant systemic disease ( screen Human Immunodeficiency Virus ( HIV ) Hepatitis B C surface antigen perform confirm eligibility , unless data obtain within one year prior begin rhFSH treatment available ) Any medical condition judgment Investigator 's sponsor may interfere absorption , distribution , metabolism excretion study drug Persistent ovarian cyst mean diameter large 20 mm ovarian endometrioma , assess U/S perform prior begin rhFSH treatment Severe endometriosis ( American Fertility Society Classification Stage III IV ) World health organization ( WHO ) Group I anovulation Pelvic inflammatory disease within 1 year prior begin rhFSH treatment Treatment clomiphene citrate gonadotrophin within 1 month prior begin rhFSH treatment Abnormal undiagnosed gynecological bleeding Known allergy hypersensitivity human gonadotrophins preparation Known current substance abuse Previous participation study simultaneous participation another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Ovulation induction</keyword>
	<keyword>Recombinant human Luteinizing Hormone ( r-hLH )</keyword>
	<keyword>Urinary human Chorionic Gonadotrophin ( u-hCG )</keyword>
	<keyword>Recombinant human Follicle Stimulating Hormone ( Gonal-f速 )</keyword>
</DOC>